Bladder Data Presented at Urology Conference and Abstracts Accepted for Upcoming AACR Meeting
Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to report that Professor Hardev Pandha has presented positive updated findings on its Phase 1 trial of CAVATAK in non muscle invasive bladder cancer ('CANON' trial). The data was presented at theAnnual EAU Congressin Munich on March 14. Further details in the announcement available on ourwebsite.

The company has also been successful in having three abstracts accepted for presentation at theAmerican Association for Cancer Research (AACR) Annual Meeting 2016, April 16 to 20. Further details in the announcement here. The full clinical trial abstracts will be available on theAACR meeting websiteFriday April 15 Eastern US time (Saturday April 16 Sydney time).

Enquiries

Dr Malcolm McColl
02 9988 4000
Website:www.viralytics.com

Viralytics Limited issued this content on 17 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 March 2016 08:24:26 UTC